|
186 Products |
| 186 Products |
|
1696 Diseases |  |
94663 News |  |
| «12...1052105310541055105610571058105910601061106210631064» |
- Rituxan (rituximab) / Roche
Enrollment open: S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma (clinicaltrials.gov) - Nov 20, 2011
P2, N=180, Recruiting, Sponsor: Southwest Oncology Group
Not yet recruiting --> Recruiting
- | Enrollment open: MYRE: Studies in Patients With Multiple Myeloma and Renal Failure Due to Myeloma Cast Nephropathy (clinicaltrials.gov) - Nov 20, 2011
P3, N=284, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
New P4 trial: AUSTRI: SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma. (clinicaltrials.gov) - Nov 17, 2011
P4, N=11664, Recruiting, Sponsor: GlaxoSmithKline
- ||| paricalcitol / Generic mfg.
Trial completion: Oral Paricalcitol in Kidney Transplant Recipients (clinicaltrials.gov) - Nov 17, 2011
P=N/A, N=100, Completed, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Decadron (dexamethasone) / Merck (MSD)
New P4 trial: Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting (clinicaltrials.gov) - Nov 16, 2011
P4, N=122, Completed, Sponsor: Sergio Bergese
- ||| Farydak (panobinostat) / Secura Bio
Enrollment closed, Combination therapy: MACS1271: Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma (clinicaltrials.gov) - Nov 16, 2011
P4, N=55, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- veliparib (ABT-888) / AbbVie
New P1 trial, Combination therapy, PARP Biomarker: Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma (clinicaltrials.gov) - Nov 15, 2011
P1, N=42, Recruiting, Sponsor: Alberta Health Services
- ||||| Dulera (mometasone/formoterol) / Merck (MSD), Novartis
New P4 trial, Monotherapy: SPIRO: A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241) (clinicaltrials.gov) - Nov 14, 2011
P4, N=11664, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
- PF-06291874 / Pfizer
New P1 trial: A Single Dose Study Of PF-06291874 In Healthy Adult Subjects (clinicaltrials.gov) - Nov 13, 2011
P1, N=9, Terminated, Sponsor: Pfizer
- ||||||| Breo Ellipta (fluticasone furoate / vilanterol) / GSK, Innoviva
Trial completion: Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics (clinicaltrials.gov) - Nov 13, 2011
P3, N=612, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||||||| Triesence (triamcinolone acetonide injectable suspension) / Novartis, Ilaris (canakinumab) / Novartis
New P3 trial: β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3) (clinicaltrials.gov) - Nov 9, 2011
P3, N=200, Completed, Sponsor: Novartis Pharmaceuticals
- ||||||| Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
Trial completion: Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray (clinicaltrials.gov) - Nov 9, 2011
P3, N=327, Completed, Sponsor: Sunovion
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Kinaction (masitinib) / AB Science
New P3 trial, Combination therapy: A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma (clinicaltrials.gov) - Nov 9, 2011
P3, N=300, Recruiting, Sponsor: AB Science
- Clinical: Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis (clinicaltrials.gov) - Nov 8, 2011
P=N/A, N=10, Recruiting, Sponsor: Wake Forest School of Medicine
- |||||||||| Nasonex (mometasone furoate nasal spray) / Merck (MSD)
New P3 trial: Efficacy and Safety of Mometasone Furoate Plus Azelastine HCl Combination Versus Mometasone Furoate Alone or Azelastine Alone in Patients With Perennial Allergic Rhinitis (clinicaltrials.gov) - Nov 7, 2011
P3, N=347, Completed, Sponsor: Hanlim Pharm. Co., Ltd.
- hydrocortisone / Generic mfg., propranolol / Generic mfg.
Trial completion: Reversal of Acute β-Blocker Induced Bronchoconstriction (clinicaltrials.gov) - Nov 7, 2011
P4, N=14, Completed, Sponsor: University of Dundee
Active, not recruiting --> Completed Recruiting --> Completed
- | Dysport (abobotulinumtoxinA) / Ipsen
New P2 trial: Botulinum Toxin Type A (BT-A) in Hemiplegic Shoulder Pain Versus Steroid (clinicaltrials.gov) - Nov 6, 2011
P2, N=52, Not yet recruiting, Sponsor: The Foundation Institute San Raffaele G. Giglio of Cefal
- budesonide / Generic mfg.
Trial completion: Budesonide in Treating Patients With Lung Nodules at High Risk of Developing Lung Cancer (clinicaltrials.gov) - Nov 3, 2011
P2, N=225, Completed, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed Active, not recruiting --> Completed
- ||||| Vizimpro (dacomitinib) / Pfizer
New P2 trial, Adverse events, Patient reported outcomes, Metastases: ARCHER 1042: Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO (clinicaltrials.gov) - Nov 3, 2011
P2, N=184, Recruiting, Sponsor: Pfizer
- Emend intravenous (fosaprepitant) / Merck (MSD), Ono Pharma
Enrollment change: Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183) (clinicaltrials.gov) - Nov 1, 2011
P1, N=16, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed N=24 --> 16
- | carfilzomib / Generic mfg., pomalidomide / Generic mfg.
Clinical: A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Nov 1, 2011
P1/2, N=117, Recruiting, Sponsor: Academic Myeloma Consortium
- | quisinostat (JNJ 26481585) / ChemRar, Viriom
New P1 trial, Combination therapy, Epigenetic controller: A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma (clinicaltrials.gov) - Nov 1, 2011
P1, N=18, Completed, Sponsor: Janssen Research & Development, LLC
- |||| fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
Trial completion: Fall Epidemic Viral Pediatric Study (clinicaltrials.gov) - Nov 1, 2011
P4, N=339, Completed, Sponsor: GlaxoSmithKline
N=24 --> 16 Active, not recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion: RaScaL: Ranibizumab and Peripheral Scatter Laser in Patients With Diabetic Macular Edema and Peripheral Nonperfusion (clinicaltrials.gov) - Oct 31, 2011
P2, N=30, Completed, Sponsor: Retina Associates of Florida, P.A.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| ulocuplumab (BMS-936564) / BMS
Enrollment open, Combination therapy: Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Oct 30, 2011
P1, N=64, Recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| triamcinolone acetonide / Generic mfg.
Enrollment change: Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR) (clinicaltrials.gov) - Oct 27, 2011
P4, N=299, Completed, Sponsor: Sanofi
Not yet recruiting --> Recruiting N=408 --> 299
- ||||| fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
New P4 trial: VESTRI: 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old (clinicaltrials.gov) - Oct 27, 2011
P4, N=6200, Recruiting, Sponsor: GlaxoSmithKline
- |||| triamcinolone acetonide / Generic mfg.
Trial completion: Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR) (clinicaltrials.gov) - Oct 27, 2011
P4, N=299, Completed, Sponsor: Sanofi
N=408 --> 299 Active, not recruiting --> Completed
- Sylvant (siltuximab) / Jazz
Trial withdrawal, Combination therapy: A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Oct 27, 2011
P3, N=0, Withdrawn, Sponsor: Centocor, Inc.
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- dexamethasone / Generic mfg., melphalan / Generic mfg., lenalidomide / Generic mfg.
Trial termination: Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma (clinicaltrials.gov) - Oct 27, 2011
P2, N=8, Terminated, Sponsor: New York University School of Medicine
Not yet recruiting --> Withdrawn Active, not recruiting --> Terminated; Due to slow accrual
- ||||||| Breo Ellipta (fluticasone furoate / vilanterol) / GSK, Innoviva
Trial completion: A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Oct 27, 2011
P3, N=1635, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Terminated; Due to slow accrual Active, not recruiting --> Completed
- ||||| fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
New P2 trial: Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate and Salmeterol Combination Product Delivered in a Capsule-based Inhaler and in a Multi-dose Dry Powder Inhaler in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients. (clinicaltrials.gov) - Oct 26, 2011
P2, N=60, Completed, Sponsor: GlaxoSmithKline
- hydrocortisone / Generic mfg.
New P2 trial: Cortisone Treatment for the Prevention of Postoperative Pancreatitis and Pancreatitis-induced Complications After Pancreaticoduodenectomy and Distal Pancreatic Resection (clinicaltrials.gov) - Oct 25, 2011
P2, N=0, Enrolling by invitation, Sponsor: Tampere University Hospital
- | fluticasone / Generic mfg.
Trial completion: Topical Steroid Treatment for Eosinophilic Esophagitis (clinicaltrials.gov) - Oct 25, 2011
P2, N=42, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Active, not recruiting --> Completed
- methylprednisolone oral / Generic mfg.
Clinical: A Bioequivalence Study Comparing Methylprednisolone Suspension to Methylprednisolone Tablets Under Fed Conditions (clinicaltrials.gov) - Oct 25, 2011
P1, N=16, Withdrawn, Sponsor: Pfizer
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- | AZD5423 / AstraZeneca
Trial completion: A Study in Healthy Subjects and Mild Asthmatics to Investigate Pharmacokinetics of AZD5423 When Administered in Different Ways (clinicaltrials.gov) - Oct 25, 2011
P1, N=12, Completed, Sponsor: AstraZeneca
Not yet recruiting --> Withdrawn Recruiting --> Completed
- | Oncaspar liquid (pegaspargase) / Servier
Clinical: Treatment of Acute Lymphoblastic Leukemia in Children (clinicaltrials.gov) - Oct 24, 2011
P3, N=800, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Completed N=544 --> 800
- | Nanocort (liposomal prednisolone) / Galapagos, Enceladus
Clinical: Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS) (clinicaltrials.gov) - Oct 23, 2011
P2, N=90, Suspended, Sponsor: Galapagos NV
N=544 --> 800 Recruiting --> Suspended
- methylprednisolone oral / Generic mfg.
Clinical: A Bioequivalence Study Comparing Methylprednisolone Suspension To Methylprednisolone Tablets (clinicaltrials.gov) - Oct 23, 2011
P1, N=16, Withdrawn, Sponsor: Pfizer
Recruiting --> Suspended Not yet recruiting --> Withdrawn
- dexamethasone / Generic mfg., lenalidomide / Generic mfg.
New P2 trial: Pilot Study to Establish Safety & Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL) (clinicaltrials.gov) - Oct 23, 2011
P2, N=24, Recruiting, Sponsor: University College, London
- ||| montelukast / Generic mfg., fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
Enrollment change: Safety and Efficacy Study Adding GSK2190915 to Mid-dose Inhaled Corticosteroid/Long Acting Beta Agonist Combination Treatment for Asthma (clinicaltrials.gov) - Oct 20, 2011
P2, N=145, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Withdrawn N=120 --> 145
- |||||||||| Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
New P3 trial: A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR) (clinicaltrials.gov) - Oct 20, 2011
P3, N=852, Completed, Sponsor: Sunovion
- |||| montelukast / Generic mfg., fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
Trial completion: Safety and Efficacy Study Adding GSK2190915 to Mid-dose Inhaled Corticosteroid/Long Acting Beta Agonist Combination Treatment for Asthma (clinicaltrials.gov) - Oct 20, 2011
P2, N=145, Completed, Sponsor: GlaxoSmithKline
N=120 --> 145 Active, not recruiting --> Completed
- || Korlym (mifepristone) / Corcept Therap
Trial completion: SEISMIC: A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome (clinicaltrials.gov) - Oct 20, 2011
P3, N=50, Completed, Sponsor: Corcept Therapeutics
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Bufomix Easyhaler (budesonide/formoterol dry powder inhaler) / Orion Corp
Trial completion: Phase I Pharmacokinetic Study (BF-BLOCK) (clinicaltrials.gov) - Oct 19, 2011
P1, N=20, Completed, Sponsor: Orion Corporation, Orion Pharma
Active, not recruiting --> Completed Recruiting --> Completed
- Rituxan (rituximab) / Roche
New P2 trial: Intensive induction treatment with B-cell antibody (rituximab), chemotherapy (Ara-C) and steroids (dexamethasone) followed by high dose chemotherapy and autologous transplantation in aggressive mantle cell lymphoma patients younger than 66 years. (EUDRACT) - Oct 18, 2011
P2, N=10, Ongoing, Sponsor: Nordic Lymphoma Group
- ||||| Reqorsa (quaratusugene ozeplasmid) / Genprex
New P1/2 trial, Metastases: TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer (clinicaltrials.gov) - Oct 18, 2011
P1/2, N=57, Recruiting, Sponsor: Genprex, Inc.
- methylprednisolone oral / Generic mfg.
Clinical: A Bioequivalence Study Comparing Methylprednisolone Suspension To Methylprednisolone Tablets Under Fasting Conditions (clinicaltrials.gov) - Oct 17, 2011
P1, N=16, Withdrawn, Sponsor: Pfizer
Recruiting --> Completed Not yet recruiting --> Withdrawn
- |||||||||| Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
New P3 trial: Effect of High Dose Ciclesonide on Asthma Control (clinicaltrials.gov) - Oct 17, 2011
P3, N=450, Active, not recruiting, Sponsor: Takeda
- |||||||||| budesonide / Generic mfg.
New P3 trial: Safety and Maintenance Study of Entocort for Children With Crohn's Disease (clinicaltrials.gov) - Oct 16, 2011
P3, N=55, Completed, Sponsor: AstraZeneca